Table 4. Analysis of overall survival by HRD phenotypes.
| All patients | High grade serous | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariate-adjusted | Covariate adjusted | |||||||||||
| N | N (%) deaths | HR (95% CI) | P value | HR (95% CI) | P value | N | N(%) deaths | HR (95% CI) | P value | HR (95%CI) | P value | |
| By HRD | ||||||||||||
| NAD | 213 | 131 (62%) | ref | 0.27 | ref | 0.04 | 146 | 100 (68%) | ref | 0.05 | 0.03 | |
| HRD | 143 | 84 (59%) | 0.86 (0.65,1.13) | 0.73 (0.54,0.98) | 118 | 74 (63%) | 0.74 (0.55,1.00) | 0.70 (0.51,0.97) | ||||
| By Type of Alteration | ||||||||||||
| None | 213 | 131 (62%) | ref | 0.75 | ref | 0.18 | 146 | 100 (68%) | ref | 0.27 | ref | 0.13 |
| Germline mutation | 82 | 48 (59%) | 0.89 (0.64,1.24) | 0.81 (0.57,1.15) | 68 | 44 (65%) | 0.81 (0.56,1.15) | 0.80 (0.56,1.16) | ||||
| Somatic mutation | 9 | 4 (44%) | 0.67 (0.25,1.82) | 0.56 (0.20,1.54) | 7 | 3 (43%) | 0.47 (0.15,1.48) | 0.42 (0.13, 1.33) | ||||
| Methylation | 50 | 32 (64%) | 0.88 (0.60,1.30) | 0.65 (0.42,1.02) | 41 | 27 (66%) | 0.74 (0.49,1.14) | 0.63 (0.39,1.02) | ||||
| By Germline Mutation | ||||||||||||
| Non-carrier | 816 | 466 (57%) | ref | 0.37 | ref | 0.09 | 550 | 367 (67%) | ref | 0.20 | 0.40 | |
| BRCA1 | 30 | 19 (63%) | 0.99 (0.62, 1.56) | 1.16 (0.72, 1.85) | 27 | 17 (63%) | 0.75 (0.46,1.22) | 1.07 (0.65,1.76) | ||||
| BRCA2 | 27 | 14 (52%) | 0.79 (0.46, 1.34) | 0.64 (0.38, 1.10) | 23 | 14 (61%) | 0.77 (0.45,1.32) | 0.76 (0.45,1.30) | ||||
| RAD51C | 23 | 12 (52%) | 0.63 (0.36, 1.12) | 0.58 (0.33, 1.04) | 18 | 12 (67%) | 0.62 (0.35,1.10) | 0.66 (0.37,1.18) | ||||
Women with VUS in any of the three genes were included in the NAD and non-carrier groups; results did not differ when these individuals were excluded from the analyses; adjusted results were adjusted for age at diagnosis, debulking status, stage, grade (low/high), ascites present at surgery, and menopausal status including categories for patients with missing data.